Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.

The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.

The present invention provides a salt of demethyl tramadol, i.e., a compound represented by formula (I) or a solvate thereof, a pharmaceutical composition comprising the compound represented by formula (I) or the solvate thereof, and a use of the compound represented by formula (I) or the solvate thereof or the pharmaceutical composition in the treatment of moderate to severe pain. The compound or pharmaceutical composition of the present invention can stably release a drug having analgesic activity in a body for a long period of time, can be conveniently used by doctors and patients while exerting pharmacological effects, and has good medication compliance.

##STR00001##

The present invention provides a salt of demethyl tramadol, i.e., a compound represented by formula (I) or a solvate thereof, a pharmaceutical composition comprising the compound represented by formula (I) or the solvate thereof, and a use of the compound represented by formula (I) or the solvate thereof or the pharmaceutical composition in the treatment of moderate to severe pain. The compound or pharmaceutical composition of the present invention can stably release a drug having analgesic activity in a body for a long period of time, can be conveniently used by doctors and patients while exerting pharmacological effects, and has good medication compliance.

##STR00001##

Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

Provided are a dezocine derivative represented by Formula I, or a tautomer, optical isomer, nitrogen oxide, solvate, pharmaceutically acceptable salt or prodrug thereof, as well as a pharmaceutical composition containing the same, preparations thereof, and medical use thereof, and the structure of Formula I is as below:

##STR00001##

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.